LITIGATOR IN THE SPOTLIGHT
Thousands of patents on human genes looked a little shakier after a recent landmark victory by the American Civil Liberties Union’s senior national staff counsel Christopher Hansen. Last year, representing several medical organizations and patients, Hansen sued the U.S. Patent and Trademark Office and Myriad Genetics, Inc., in federal district court in Manhattan, seeking to overturn the patents that the biopharmaceutical company holds on two genes linked to breast and ovarian cancer. At a summary judgment hearing in February, Hansen argued that the Myriad patents are invalid because genes are products of nature. Although the defendants argued that the process of isolating the genes changes them and makes them patentable, Judge Robert Sweet agreed with Hansen, the first time that a court has found that genes cannot be patented. The defendants are appealing.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]